Dabigatran etexilate – 5 mg

Brand:
Cayman
CAS:
211915-06-9
Storage:
-20
UN-No:
Non-Hazardous - /

Dabigatran etexilate is a double prodrug that undergoes in vivo hydrolytic cleavage to produce dabigatran (Item No. 17133), a potent thrombin inhibitor (Ki = 4.5 nM).{28063,28064} Dabigatran also inhibits trypsin (Ki = 50.3 nM), but only weakly inhibits other serine proteases.{28063,28064} The prodrug dabigatran etexilate shows antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action.{28064} It is not metabolized by cytochrome P450 isozymes and has a low potential for drug-drug interactions.{28064}  

 

Out of stock

SKU: - Category:

Description

A double prodrug that undergoes in vivo hydrolytic cleavage to produce dabigatran, a potent thrombin inhibitor (Ki = 4.5 nM); shows antithrombotic efficacy in animal models of thrombosis, with a rapid onset of action


Formal name: N-[[2-[[[4-[[[(hexloxy)carbonyl]amino]iminomethyl]phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-β-alanine, ethyl ester

Synonyms:  BIBR 1048

Molecular weight: 627.7

CAS: 211915-06-9

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Small Molecule Inhibitors|Blood Coagulation Factors||Research Area|Cardiovascular System|Blood|Coagulation & Hemostasis||Research Area|Cardiovascular System|Blood|Thrombosis||Research Area|Cell Biology|Proteolysis|Cytosolic & Secreted Proteases